Algorithme selects VCT to stop duplicate enrollment in clinical trials
Algorithme Pharma USA, an Altasciences company, has selected Verified Clinical Trials (VCT), the global clinical trial research subject database registry, to counter attempts at duplicate enrollment in clinical trial research.
The majority of phase I units in North America utilize Verified Clinical Trials, making it the largest North American clinical research subject database registry in both early and late phase clinical trials. Algorithme Pharma USA joins a vast network of research sites and pharmaceutical companies on a national and global level to prevent duplicate enrollment in clinical trials.
Simultaneously enrolling in multiple clinical trials, also known as duplicate enrollment in clinical trials, has become a serious problem in the clinical research world, as research volunteers attempt to jump from one study to another without waiting for the appropriate amount of time to lapse between studies. That process is typically done in an effort to earn more money or receive free care. By doing so, others are placed at risk, including the drug manufacturer, the research site and, most importantly, the volunteer. Furthermore, it may result in issues with the data quality.
Algorithme Pharma USA has taken a major step by choosing the VCT system to stop professional research subjects from duplicate enrollment in clinical trials. Algorithme Pharma USA is committed to volunteer safety and data quality; hence implementing the research subject database registry system to increase safety measures by preventing numerous protocol deviations.
Dr. Mitchell Efros, CEO of VCT, said, “Algorithme Pharma USA is the first clinical research unit in North Dakota to utilize a research subject database registry to prevent duplicate enrollment in clinical trials. By joining forces with Verified Clinical Trials, Algorithme Pharma USA has made a serious commitment to preventing duplicate enrollment in clinical trials as well as other protocol deviations while promoting subject safety and improving data quality.”
Algorithme Pharma USA President and CEO James Carlson said, “Having been in the clinical trial research business for over three decades, I am well aware of the issue of duplicate enrollment. Although we have exerted every effort to prevent it, never before have we had such a far reaching tool as offered by Verified Clinical Trials. We look forward to a close working relationship with Verified Clinical Trials.”